Gast ::
| Hauptseite > Normsätze > Projekte > Datensatz #243986 > print |
| 001 | 243986 | ||
| 005 | 20230827173245.0 | ||
| 024 | 7 | _ | |a G:(EU-Grant)963976 |d 963976 |2 CORDIS |
| 024 | 7 | _ | |a G:(EU-Call)ERC-2020-PoC |d ERC-2020-PoC |2 CORDIS |
| 024 | 7 | _ | |a corda__h2020::963976 |2 originalID |
| 035 | _ | _ | |a G:(EU-Grant)963976 |
| 150 | _ | _ | |a Commercial assessment of a novel protocol for epilepsy characterisation with temporally interfering electric fields |y 2021-03-01 - 2023-02-28 |
| 372 | _ | _ | |a ERC-2020-PoC |s 2021-03-01 |t 2023-02-28 |
| 450 | _ | _ | |a CONECTIF |w d |y 2021-03-01 - 2023-02-28 |
| 510 | 1 | _ | |0 I:(DE-588b)5098525-5 |a European Union |2 CORDIS |
| 680 | _ | _ | |a The ERC StG project “Epilepsy Controlled with Electronic Neurotransmitter Delivery (EPI-Centrd)” is focused on improved therapeutic intervention in drug-resistant patients with surgically-complicated forms of epilepsy. These patients represent a large demographic needing new commercial solutions, as there are fifty million people in the world with epilepsy and up to 50 cases of new-onset epilepsy per 100,000 people each year, where 30% of these cases are patients with drug-resistant epilepsy. Although EPI-Centrd provides state-of-the-art treatments for epileptic zones in the brain of drug-resistant patients, it does not include technology for improved identification of such epileptic zones. This ERC PoC project “The Commercial Assessment of a Novel Protocol for Epilepsy Characterisation with Temporally Interfering Electric Fields (CONECTIF)” dramatically improves the traditional limitations in the identification of epileptic zones in the brain of patients by providing a simplified, less-invasive method capable of localizing epileptic tissue, including the ability to non-invasively investigate previously inaccessibility and surgically-complicated brain regions. The new method utilizing temporally interfering electric fields could have a massive commercial potential and, if successful, would dramatically improve the therapeutic targets for technologies developed in the EPI-Centrd project and for the identification of epileptic zones in other forms of epilepsy, not only in drug-resistant patients. |
| 909 | C | O | |o oai:juser.fz-juelich.de:900426 |p authority:GRANT |p authority |
| 909 | C | O | |o oai:juser.fz-juelich.de:900426 |
| 980 | _ | _ | |a G |
| 980 | _ | _ | |a CORDIS |
| 980 | _ | _ | |a AUTHORITY |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|